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Abstract
Background: The high rate of HIV-1 mutation and increasing resistance to currently available antiretroviral (ART)
therapies highlight the need for new antiviral agents. Products derived from natural sources have been shown to inhibit
HIV-1 replication during various stages of the virus life cycle, and therefore represent a potential source of novel
therapeutic agents. To expand our arsenal of therapeutics against HIV-1 infection, we investigated aqueous extract from
Sargassum fusiforme (S. fusiforme) for ability to inhibit HIV-1 infection in the periphery, in T cells and human macrophages,
and for ability to inhibit in the central nervous system (CNS), in microglia and astrocytes.
Results: S. fusiforme extract blocked HIV-1 infection and replication by over 90% in T cells, human macrophages and
microglia, and it also inhibited pseudotyped HIV-1 (VSV/NL4-3) infection in human astrocytes by over 70%. Inhibition
was mediated against both CXCR4 (X4) and CCR5 (R5)-tropic HIV-1, was dose dependant and long lasting, did not
inhibit cell growth or viability, was not toxic to cells, and was comparable to inhibition by the nucleoside analogue 2', 3'-
didoxycytidine (ddC). S. fusiforme treatment blocked direct cell-to-cell infection spread. To investigate at which point of
the virus life cycle this inhibition occurs, we infected T cells and CD4-negative primary human astrocytes with HIV-1
pseudotyped with envelope glycoprotein of vesicular stomatitis virus (VSV), which bypasses the HIV receptor
requirements. Infection by pseudotyped HIV-1 (VSV/NL4-3) was also inhibited in a dose dependant manner, although up
to 57% less, as compared to inhibition of native NL4-3, indicating post-entry interferences.
Conclusion: This is the first report demonstrating S. fusiforme to be a potent inhibitor of highly productive HIV-1
infection and replication in T cells, in primary human macrophages, microglia, and astrocytes. Results with VSV/NL4-3
infection, suggest inhibition of both entry and post-entry events of the virus life cycle. Absence of cytotoxicity and high
viability of treated cells also suggest that S. fusiforme is a potential source of novel naturally occurring antiretroviral
compounds that inhibit HIV-1 infection and replication at more than one site of the virus life cycle.
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Background
Macrophages and T cells are major targets for HIV-1 infec-
tion [1]. While macrophages are key cellular reservoir and
a source of newly replicating HIV-1 throughout the infec-
tion, a global decline in T cell population leads to the
eventual collapse of the immune system, development of
clinical manifestations of AIDS, and the ultimate death of
the host. Highly active antiretroviral therapy (HAART) has
greatly extended the lifespan of HIV-infected individuals,
however the AIDS epidemic continues to expand globally
and the long-term control of HIV-1 infection remains an
elusive goal. Current HAART regiments, with the excep-
tion of recent fusion inhibitor (T-20), include inhibitors
of two key viral enzymes, reverse transcriptase and pro-
tease [2-4]. By using combinations of reverse transcriptase
and protease inhibitors in HAART, dramatic reductions in
the level of chronic HIV-1 viremia have been achieved in
a majority of patients [2,4]. However, both reverse tran-
scriptase and protease inhibitors have significant clinical
side effects [5-7]. Initial optimism that the natural decay
of virus-producing cells in the presence of HAART would
lead to eradication of virus was short-lived [8,9]. Long-
term follow-up of HAART-treated individuals revealed
very slow rates of decline of HIV-1 in some individuals,
with continued low-level replication of virus in macro-
phages and T cells, and viral persistence in several tissue
compartments, such as the CNS, not readily accessible to
current therapies [5,9-11]. Studies in a macaque model of
simian immunodeficiency virus (SIV) viral persistence in
the brain, have suggested that in individuals on HAART
with suppressed viral load, the CNS may act as a long-
term viral reservoir [12].
HIV-1 infected human macrophages are the primary route
of virus entry into the CNS [13]. Within the CNS, active
virus replication is mediated by macrophages and micro-
glia, while astrocytes are nonproductively infected [14].
The number of astrocytes in the brain ranges up to 2 ×
1012, and while only 1% of these cells may be latently
infected, the total number of infected astrocytes contribut-
ing to neuropathology, may be substantial [15,16]. Brain
macrophages, microglia, and astrocytes have been shown
to be responsible for some of the neuropathologic mani-
festations of the HIV-associated dementia (HAD), which
develops in about 20–30% of AIDS patients [14,17].
Although HAART has decreased frequency of HAD, it does
not provide full protection or reversal of HAD [18]. Pro-
tease inhibitors and some of the nucleoside analogues
used in HAART have poor CNS penetration, and drug
resistance in this compartment has recently been
reported, further underscoring need for discovery of new
drugs [12,19,20].
Continued virus replication in the presence of HAART
increases the likelihood and frequency of generating new
multi-drug-resistant (MDR) HIV-1 strains, as demon-
strated by the observation that approximately 20% of all
new HIV-1 infections are with viruses resistant to the cur-
rently available drugs [21,22]. Consequently, concerted
efforts towards the discovery and development of novel
inhibitors of HIV-1 infection and replication must persist
if continued viral repression and possibility of virus erad-
ication are to be achieved.
We investigated a number of natural products, and identi-
fied S. fusiforme extract as a potent inhibitor of HIV-1 rep-
lication in T cells, in primary human macrophages,
microglia, and astrocytes. While many natural products
have been screened for anti-HIV activity [23,24], includ-
ing sulfated polysaccharides derived from sea algae
[25,26], S. fusiforme extract has not been investigated up
until now [27].
Results
S. fusiforme does not inhibit cell growth or viability
To establish a non-toxic working concentration, we tested
for cell growth and viability kinetics in response to treat-
ment with S. fusiforme whole aqueous extract. T cells were
treated with either 2 or 4 mg/ml S. fusiforme, 10-6 M ddC,
or were mock treated (Fig 1). In 1G5 cells, growth kinetics
remained similar, except for the highest 4 mg/ml treat-
ment on day 7 that decreased cell growth by 19% com-
pared to ddC treatment, indicating possible toxicity at this
dose (Fig 1A). In parallel we also measured cell viability
by trypan blue exclusion assay. Regardless of treatment,
cell viability remained above 90%, which was comparable
to mock treated cultures (Fig. 1B). We repeated this exper-
iment with HIV-1 infected 1G5 cells, with similar results
(not shown). Because of toxicity relevance in primary
human cells, we also measured cell growth and viability in
human peripheral blood mononuclear cells (PBMC),
with similar results (Fig 1C and 1D). Cells treated with
either 3 or 4.5 mg/ml S. fusiforme exhibited somewhat
slower growth kinetics on day 6 after treatment, as com-
pared to 1.5 mg/ml S. fusiforme, ddC or mock treated cells
(Fig 1C). However, viability of S. fusiforme and ddC
treated cells remained similar through day 6 of follow-up,
with the overall PBMC's viability declining over time, as
compared to 1G5 T cell line (compare Fig. 1D to 1B ).
Based on these results we conclude that treatment with
less than 4 mg/ml S. fusiforme extract, does not inhibit cell
growth, is not toxic to cells, and is suitable for in vitro test-
ing of HIV-1 inhibition in 1G5 cells.
S. fusiforme inhibits HIV-1 infection in T cells in a dose 
dependant manner
Next, we investigated S. fusiforme ability to inhibit HIV-1
infection in T cells. We chose 1G5 T cells, which are stably
transfected with HIV-LTR-luciferase gene construct, haveAIDS Research and Therapy 2006, 3:15 http://www.aidsrestherapy.com/content/3/1/15
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low basal level of luciferase expression and are sensitive to
HIV-1 tat activation, which makes them a useful tool for
testing HIV-1 inhibitors [28]. Cells were treated with
increasing concentrations of S. fusiforme extract and
infected with NL4-3. On day 3 after infection, equal num-
bers of viable cells were analyzed for intracellular luci-
ferase expression, and cell viability was measured by MTT
uptake assay (Fig. 2). Percent HIV-1 inhibition was calcu-
lated by comparison to control infected untreated cell cul-
tures, which expressed 18,797 relative light units (RLU) of
luciferase (not shown). Treatment with 1.5, 3, and 6 mg/
ml of S. fusiforme extract inhibited HIV-1 replication in a
dose dependant manner, by 60.4, 86.7, and 92.3%,
respectively (Fig. 2A). As expected, treatment with positive
control HIV-1 reverse transcriptase (RT) inhibitor ddC,
blocked virus replication by over 98% (not shown). In
parallel, we tested for the MTT uptake by viable cells,
which remained high regardless of S. fusiforme treatment,
and was similar to ddC, as well as to viability of mock
treated cells (Fig. 2B).
Analysis of growth kinetics and viability in T cells treated with S. fusiforme Figure 1
Analysis of growth kinetics and viability in T cells treated with S. fusiforme. 1G5 T cells were treated with 2 mg/ml or 
4 mg/ml S. fusiforme, or with 10-6 M ddC, or were mock treated. (A) Total cell number, and (B) % viable cells from total, was 
monitored at the indicated time points after infection, by trypan blue exclusion assay by counting at least 200 cells each in three 
different fields under ×20 magnification using an Olympus BH-2 fluorescence microscope. Experiment was repeated with pri-
mary human PBMC's treated with 1.5, 3, or 4.5 mg/ml S. fusiforme, or with 10-6 M ddC, or mock treated, and measured (C) 
Total cell number, and (D) % viable cells from total. PBMC's experiments are representative of 3 separate experiments, with 
SEM less than 5% (not shown).
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Based on these results we conclude that S. fusiforme treat-
ment inhibits HIV-1 replication in T cells in a dose
dependant manner, inhibition is similar to that achieved
with ddC treatment, and treatment is not toxic to cells.
S. fusiforme inhibition is non-toxic and can be sustained 
over extended periods
Next, we tested for the duration of HIV-1 inhibition in
1G5 T cells, treated with either 2 mg/ml S. fusiforme or
with 10-6 M ddC. Infection was monitored by luciferase
expression from cells equalized to same number of viable
cells by MTT assay, at the indicated time points after infec-
tion (Fig. 3A). HIV-1 infection in untreated cells gradually
increased from 16,110 RLU expressed on day 3, to 86,720
RLU on day 7 after infection, which demonstrated highly
productive and de novo HIV-1 synthesis (not shown).
Treatment with 2 mg/ml S. fusiforme inhibited this infec-
tion by 77, 99, and 99% on day 3, 5, and 7, respectively
(Fig. 3A). As expected, inhibition by ddC was 99% at each
time point tested. Based on these results we calculated
IC50 to be 0.86 mg. Similar time course inhibition results
were obtained in CEM T cells (not shown).
In parallel to infection kinetics, we also tested cell viability
by trypan blue exclusion assay (Fig. 3B). Cell viability in
S. fusiforme treated cultures remained high at 98, 94, and
97% viable cells on day 3, 5, and 7, respectively. Cell via-
bility in ddC treated cultures was similar, and measured
94, 93, and 97% viable cells on day 3, 5, and 7, which was
similar to mock treated cultures. This data confirm MTT
viability results, which were used to equalize cells to same
numbers of viable cells (not shown).
Collectively, these findings demonstrate that S. fusiforme
inhibits infection and de novo HIV-1 synthesis, through
day 7 of follow-up, and this treatment does not affect cell
viability.
S. fusiforme blocks HIV-1 transmission by direct cell-to-
cell mechanisms of infection
HIV-1 infection is spread either by free viral particles, or
100 times more efficiently by direct cell-to-cell fusion [1].
Considering that S. fusiforme inhibits HIV-1 infection in T
cells (Fig. 3), we wanted to determine its ability to block
cell-to-cell mediated viral transfer. To test this, we per-
formed two separate experiments with different cell types
(Fig 4). First, we examined the ability of HIV infected CEM
cells to fuse and spread infection to uninfected 1G5 cells
that were either mock treated, treated with 10-6 M ddC
only, or treated with increasing concentrations of S. fusi-
Dose response of HIV-1 inhibition and cell viability in T cells treated with S. fusiforme Figure 2
Dose response of HIV-1 inhibition and cell viability in T cells treated with S. fusiforme. 1G5 T cells were treated for 
24 h with increasing concentrations of S. fusiforme, or with 10-6 M ddC, as indicated; then infected with CXCR4 tropic HIV-1 
(NL4-3) at multiplicity of infection (moi) of 0.01 for 1.5 h, washed 3 times, and returned to culture with same concentrations of 
each treatment for the duration of the experiment. (A) On day 3 after infection, intracellular luciferase gene marker expression 
was measured from cell lysates adjusted to same number of viable cells by MTT. Percent inhibition of HIV-1 was calculated uti-
lizing formula in the Methods section, and plotted on the Y-axis as % Inhibition. In parallel, (B) cell viability for each treatment 
was quantified by MTT uptake, measured at 570 nm absorbance. Data are mean +/- SD of triplicates. Representative of three 
separate experiments.
0
0.2
0.4
0.6
0.8
1
1.2
0
0.2
0.4
0.6
0.8
1
1.2
M
T
T
 
u
p
t
a
k
e
 
(
a
b
s
o
r
b
a
n
c
e
 
5
7
0
n
m
)
Treatment
1.5 mg/ml S. fusiforme
3 mg/ml S. fusiforme
6 mg/ml S. fusiforme
NL4-3
ddC
Mock
1.5 mg/ml 3 mg/ml 6 mg/ml
0
20
40
60
80
100
%
 
I
n
h
i
b
i
t
i
o
n
 
(
l
u
c
i
f
e
r
a
s
e
)
S. fusiforme Treatment
A)  Dose response B)  ViabilityAIDS Research and Therapy 2006, 3:15 http://www.aidsrestherapy.com/content/3/1/15
Page 5 of 12
(page number not for citation purposes)
forme and ddC, or with S. fusiforme only. Pretreatment of
1G5 cells with 10-6 M ddC inhibits virus replication, and
therefore serves as a control for false positive luciferase
readings from free virus particle infection and replication,
however it does not prevent spread of infection by cell-to-
cell fusion. CEM and 1G5 cells were cocultivated for 24 h
at a ratio of 1:1, and examined for cell-to-cell fusion and
syncytia formation by phase contrast microcopy (A-F) or
by luciferase expression (H). As expected, many large syn-
cytia were observed in co-cultures with mock treated or
only ddC treated 1G5 cells (A and B). However, 1G5 treat-
ment with 2 mg S. fusiforme, with or without ddC, greatly
reduced cell-to cell fusion and syncytia formation (C and
E). No giant cells were detected in 1G5 cells treated with
either 4 mg/ml (D and F) or with 6 mg/ml (not shown) S.
fusiforme, with or without addition of ddC. Inhibition of
viral infection by cell-to-cell fusion was also confirmed by
decreased luciferase expression in S. fusiforme treated 1G5
cells that were cocultivated with HIV infected CEM cells
(H). CEM cells do not have the HIV-LTR-luciferase gene,
as 1G5 cells do, and therefore luciferase readings from
cocultivated cell cultures can only arise from 1G5 cells
that fused and formed giant cells with infected CEM cells.
24 h after cocultivation with untreated 1G5 cells, luci-
ferase expression measured 1.9 × 105 RLU, which repre-
sented maximal luciferase expression in the absence of
any treatment (not shown). 1G5 treatment with 10-6 M
ddC and 2, 4, or 6 mg S. fusiforme inhibited cell-to-cell
fusion, as measured by luciferase expression in 1G5 cells,
by 77, 96, and 98%, respectively (H). Inhibition was sim-
ilar in cells treated with S. fusiforme only, in the absence of
ddC, demonstrating low rate of infection by free virus,
during the 24 hours of cocultivation (not shown). In com-
parison, 1G5 cell treatment with only 10-6 M ddC, inhib-
ited luciferase expression by 69%.
In the second experiment, we cocultivated HIV infected
and untreated 1G5 cells with uninfected and treated HIV-
Time course of HIV-1 inhibition and viability in T cells Figure 3
Time course of HIV-1 inhibition and viability in T cells. 1G5 T cells were 24 h treated with either 2 mg/ml S. fusiforme, 
or with 10-6 M ddC; then infected with NL4-3 at 0.01 moi for 1.5 h, washed 3 times, and returned to culture with same con-
centration of each treatment for the duration of the experiment. On day 3 post-infection, (A) gene expression of intracellular 
luciferase was measured from cell lysates adjusted to same number of viable cells, and % inhibition calculated and plotted on 
the Y-axis. Data are mean +/- SD of triplicates. In parallel, (B) cell viability was determined by trypan blue exclusion assay by 
counting at least 200 cells each, in three different fields under ×20 magnification using an Olympus BH-2 fluorescence micro-
scope.
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LTR-GFP-expressing GHOST adherent cells [29], and
monitored for cell-to-cell fusion by GFP expression from
GHOST cells (G). After cocultivation with infected 1G5
cells, mock or only ddC treated GHOST cells can fuse, and
form syncytia that emit green florescence, which was
detected by phase fluorescence microscopy. GHOST cells
that were ddC treated and cocultivated with HIV-1
infected 1G5 cells, resulted in cell-to-cell fusion and fluo-
rescent giant cell formation as is shown by fluorescence
micrograph superimposed on the phase contrast black
and white image of the same field (G). However, as in
CEM-1G5 cocultivation experiment, no giant cells emit-
ting green fluorescence were detected in 1G5 cells coculti-
vated with GHOST cells that were treated with S. fusiforme,
with or without ddC (not shown).
Based on the results of these two different experiments, we
conclude that S. fusiforme blocks HIV-1 infection by cell-
to-cell fusion mechanism, which also prevents subse-
quent multinucleated cell formation and its associated
cytophatic effects.
Inhibition of cell-to-cell infection and syncytia formation Figure 4
Inhibition of cell-to-cell infection and syncytia formation. Uninfected 1G5 T cells were pretreated for 24 h with either 
(A) mock, (B) 10-6 M ddC, or with ddC and (B) 2 mg/ml or (C) 4 mg/ml S. fusiforme, or with S. fusiforme only at (D) 2 mg/ml or 
(E) 4 mg/ml. 1G5 cells were cocultivated at 1:1 ratio with CEM cells that were infected with NL4-3 at 0.01 moi. 24 h after coc-
ultivation, cells were examined for syncytium formation using Leica DM IL Fluo microscope, ×20 magnification (A-F). Cell cul-
tures were monitored for luciferase expression, and % inhibition was calculated from maximal luciferase expression from 
untreated 1G5 cells (1.9 × 105 RLU, not shown), which was plotted and is indicated on top of each bar (H). Data are mean +/- 
SD of triplicates. Uninfected adherent GHOST [29] cells were ddC treated and cocultivated at 1:1 ratio with HIV infected 1G5 
cells for 24 h, and examined for syncytia formation by green fluorescence (G). Image shows fluorescence micrograph taken of 
a green fluorescent giant cell, which was superimposed on the same field phase contrast black and white image.
Cell-to-cell InhibitionAIDS Research and Therapy 2006, 3:15 http://www.aidsrestherapy.com/content/3/1/15
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S. fusiforme inhibits HIV-1 infection in primary human 
macrophages and brain microglia
Macrophages and brain microglia are productively
infected with R5-tropic HIV-1, and are considered to be
the primary source of virus replication in the periphery
and in the CNS [1]. Because of their importance to HIV
infection, we investigated ability of S. fusiforme extract to
inhibit virus infection in these cells. Primary human mac-
rophages or microglial cell cultures were treated with 1
mg/ml S. fusiforme extract and infected with primary R5
isolate ADA [30]. Infection was monitored by measuring
viral p24 concentrations in cell-free supernatants, at the
indicated time points after infection (Fig. 5).
In infected and untreated macrophage cell cultures, virus
levels steadily increased from 19,097 pg of p24/ml on day
4, to a peak of infection on day 14, measuring 163,740 pg
of p24/ml, indicating productive HIV-1 infection and de
novo  virus synthesis (not shown). However, treatment
with 1 mg/ml S. fusiforme extract inhibited ADA replica-
tion (dark bars) by over 90% through day 14 after infec-
tion, which was comparable to the inhibition with ddC
treatment (Fig. 5A).
Next, we treated fetal microglial cell cultures with either 1
mg/ml S. fusiforme, or 10-6 M ddC, or mock treated, and
monitored infection kinetics by p24 production in cell-
free supernatants at the indicated time points after infec-
tion (Fig. 5B). As in T cells and macrophages, infected and
mock treated microglia were productively infected as
demonstrated by steadily increasing p24 production that
reached a peak on day 14 with 2,313 pg of p24/ml (not
shown). Treatment with S. fusiforme inhibited this infec-
tion by 75% on day 3, by over 90% on day 7 and 10, and
Inhibition of HIV-1 expression in human macrophages and microglia Figure 5
Inhibition of HIV-1 expression in human macrophages and microglia. Either, (A) human macrophages or (B) human 
fetal microglia were 24 h treated with 1 mg/ml S. fusiforme, or with 10-6 M ddC, infected with primary CCR5-tropic isolate 
ADA at 0.2 pg of p24/cell for 2 h, washed 3 times, and returned to culture with same concentration of each treatment for the 
duration of the experiment. At the indicated time points after infection HIV-1 expression was monitored by p24 production in 
cell-free supernatants by ELISA, % inhibition calculated as described in Methods and plotted on the y-axis. Data are mean +/- 
SD of triplicates. Representative of 2 experiments.
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by 81% on day 14 after infection. By comparison, virus
inhibition by ddC was 72% on day 3, and thereafter
remained above 90%.
In parallel to infection kinetics, we monitored cell viabil-
ity by MTT assay, which remained high and was similar to
uninfected cell cultures (not shown). Based on these
results we conclude that S. fusiforme is a potent inhibitor
of R5-tropic HIV-1 infection in primary human macro-
phages and microglia: inhibition is long lasting, not toxic
to cells, and with similar inhibition kinetics to those
observed in T cells (Fig. 3A).
S. fusiforme inhibits HIV-1 infection during entry and 
post-entry events of virus life cycle
Collectively, our results demonstrate that S. fusiforme
extract robustly inhibits HIV-1 infection in a number of
cell types, and in a number of infection scenarios. In order
to determine how this inhibition works, we tested
whether the extract could block infection at a post-entry
level of virus replication.
HIV-1 pseudotyped with the vesicular stomatitis virus G-
protein (VSV-G) can infect cells without interacting with
CD4 and co-receptors. We extended HIV-1 tropism by
pseudotyping native HIV-1 (NL4-3) with VSV-G envelope
(VSV/NL4-3), which produced native NL4-3 with heterol-
ogous envelope glycoproteins that bind to commonly
expressed cellular receptors. VSV/NL4-3 virus gains access
to the cytoplasm by fusing out of endocytic vesicles [31].
Therefore, any block to VSV/NL4-3 replication would sug-
gest post-entry inhibition. We treated T cells with increas-
ing doses of S. fusiforme, infected with NL4-3 or VSV/NL4-
3, and monitored infection by luciferase gene expression
on day 3 after infection (Fig. 6A). To our surprise, S. fusi-
forme mediated dose dependant inhibition of VSV/NL4-3,
Inhibition of infection with pseudotyped HIV-1 in T cells andhuman astrocytes Figure 6
Inhibition of infection with pseudotyped HIV-1 in T cells andhuman astrocytes. (A) 1G5 T cells were treated with 
increasing concentrations of S. fusiforme and infected with either NL4-3 at 0.01 moi or with VSV/NL4-3 at 0.005 moi. 3 days 
after infection, % inhibition was calculated from luciferase expression from cell lysates adjusted to same number of viable cells 
by MTT. (B) Human fetal CD4 negative astrocytes were treated with 1 mg/ml S. fusiforme, or with 10-6 M ddC, infected with 
VSV/NL4-3 at 0.4 moi, and infection kinetics monitored by p24 expression in cell free supernatants at the indicated time points 
post infection. Data are mean +/- SD of triplicates. Representative of 2 experiments.
1 mg/ml 2 mg/ml 3 mg/ml
0
20
40
60
80
100
 
%
 
I
n
h
i
b
i
t
i
o
n
 
(
l
u
c
i
f
e
r
a
s
e
)
S. fusiforme Treatment
54
27
78
33
94
63
NL4-3 VSV/NL4-3
A) T cells B) Human astrocytes
36 1 2
0
20
40
60
80
100
%
 
I
n
h
i
b
i
t
i
o
n
 
(
p
2
4
)
Days post infection
71
99
40
99
54
99
S. fusiforme ddCAIDS Research and Therapy 2006, 3:15 http://www.aidsrestherapy.com/content/3/1/15
Page 9 of 12
(page number not for citation purposes)
inhibiting at 26.6, 32.8, and 62.6% that corresponded to
1, 2, and 3 mg/ml S. fusiforme extract treatment, respec-
tively (Fig. 6A, light bars). However, overall inhibition of
pseudotyped virus was markedly lower as compared to
inhibition of native NL4-3, which was inhibited by 53, 78,
and 93% (dark bars). Considering that pseudotyped VSV/
NL4-3 has no cell surface entry restrictions, these data sug-
gest that: 1) S. fusiforme blocks at a post-entry step of viral
replication, and 2) inhibition is also mediated during
entry process, as suggested by difference in the levels of
inhibition between native NL4-3 and VSV/NL4-3 infec-
tions.
To confirm and extend the finding of post-entry inhibi-
tion in T cells, we tested for inhibition of VSV/NL4-3 in
CD4-negative primary cells. Human astrocytes are CD4-
negative cells that are nonproductively infected by HIV-1
in vivo [16], and in vitro [32-34]. However, we showed
that, in vitro, these cells fully support productive virus rep-
lication after entry restriction has been bypassed [35].
Infection with VSV/NL4-3 productively infects majority of
astrocytes, and serves as model system to study HIV-1 rep-
lication in these cells [35]. We infected primary human
astrocytes with VSV/NL4-3, and monitored infection
kinetics at the indicated time points after infection, by
measuring p24 production in cell-free culture superna-
tants (Fig. 6B). Peak of infection was reached on day 12
with 71,000 pg of p24/ml produced in the infected and
untreated cell culture, indicating ongoing virus replication
(data not shown). Consistent with post-entry inhibition
observed in T cells (Fig. 6A), treatment with 1 mg/ml S.
fusiforme extract also inhibited post-entry virus replication
in primary human astrocytes, by 71, 40, and 54%, on day
3, 6, and 12, respectively (Fig. 6B).
These data support our hypothesis that in addition to
inhibiting viral entry, S. fusiforme extract also blocks viral
replication during a post-entry event of the virus life cycle.
However, the exact mechanisms of either entry or post-
entry inhibition need to be further investigated.
Discussion
The high rate of HIV-1 mutation and increasing resistance
to currently available antiretroviral therapies underscores
the need for new antiviral agents. The AIDS pandemic has
been especially devastating in the Third world countries
that can least afford or have easy access to current thera-
pies, demonstrating a need for affordable treatments
aimed at preventing HIV infection [36]. To expand search
for novel inhibitors of HIV infection and replication, we
studied and identified naturally occurring S. fusiforme
extract as an efficient inhibitor of HIV-1 replication in T
cells, in primary human macrophages, microglia, and
astrocytes.
First, we demonstrated that S. fusiforme aqueous extract
does not inhibit cell growth, is not toxic to cells, and was
therefore suitable for further in vitro studies of HIV-1 inhi-
bition (Fig. 1). Because it may be easier to block inefficient
low level virus replication, we ensured that the observed
inhibition was mediated against productive and de novo
viral synthesis, by monitoring virus replication by either
cell free p24 production or intracellular luciferase reporter
gene expression. In T cells, S. fusiforme extract inhibited
HIV-1 replication up to 90%, in a dose dependant manner
(Fig. 2). This inhibition was long lasting, up to 7 days of
follow-up, and was similar to the levels of inhibition
observed with ddC treatment (Fig. 3).
In vivo, one mechanism of HIV-1 infection and viral
spread is by a direct cell-to-cell fusion, between infected
and uninfected cell [37]. To investigate possible inhibi-
tion of this mechanism of infection, in two separate exper-
iments with different cell types, we cocultivated S.
fusiforme treated cells, with HIV infected cells, and moni-
tored for syncytia formation by microscopy, and for viral
replication by luciferase expression (Fig 4). In both exper-
iments, treatment with S. fusiforme, with or without ddC
control for free virus infection, prevented cell-to-cell
fusion and inhibited infection, in a dose dependant man-
ner. These results demonstrate ability of S. fusiforme to
inhibit physiologically relevant mechanism of spreading
infection.
Infected macrophages act as a bridge between the periph-
ery and the CNS, by spreading HIV-1 infection to micro-
glia and astrocytes in the CNS [14]. Treatment with 1 mg/
ml S. fusiforme extract inhibited active R5-tropic virus rep-
lication by 90%, in primary human macrophages and
microglial cell cultures (Fig 5). In primary human astro-
cytes, S. fusiforme ihibited VSV/NL4-3 entry independent
infection by 71%, which also suggested post entry inhibi-
tion of virus replication in these cells (Fig 6B). S. fusiforme
did not inhibit cell growth or viability in these cells, which
was consistent with results in T cells (Fig 1 and 2). These
results demonstrate ability of S. fusiforme extract to inhibit
HIV-1 replication in the two relevant cell types in the CNS,
microglia and astrocytes. In this context, it would be of
interest to determine whether S. fusiforme is capable of
crossing the blood-brain barrier (BBB), and be an effective
treatment in this important viral reservoir.
Because it was not clear which step of the virus life cycle S.
fusiforme blocks, we investigated possibility of post entry
inhibition. We tested for inhibition of infection with VSV-
G pseudotyped HIV-1, which has been used to bypasses
any entry restrictions [31,35]. Treatment with increasing
doses of S. fusiforme inhibited VSV/NL4-3 infection in T
cells in a dose dependant manner (Fig. 6A). However,
compared to inhibition of native HIV-1, inhibition ofAIDS Research and Therapy 2006, 3:15 http://www.aidsrestherapy.com/content/3/1/15
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VSV/NL4-3 was markedly lower, up to 57% lower, indicat-
ing interference with post entry steps of virus life cycle. We
extended this finding by infecting CD4-negative human
astrocytes with VSV/NL4-3, which was also inhibited by
71% (Fig 6B). Consistent with lower post entry inhibition
in T cells, post entry inhibition in astrocytes was also
lower, as compared to 99% inhibition with ddC treat-
ment. The reasons for these inhibition differences are not
clear, but given that native NL4-3 has entry restrictions
and pseudotyped VSV/NL4-3 does not, we interpret these
results to mean that S. fusiforme mediates HIV-1 inhibi-
tion during both entry and post entry steps of virus life
cycle. However, the exact mechanisms of this inhibition
need to be investigated. Considering S. fusiforme inhibi-
tion in different cell types, and with different mechanisms
of action, we further postulate that this complex aqueous
mixture contains more than one biologically active mole-
cule mediating the observed HIV-1 inhibition.
Conclusion
S. fusiforme extract is a potent inhibitor of HIV-1 infection
in T cells, in human macrophages, microglia, and astro-
cytes. Inhibition is mediated during both entry and post
entry events of the virus life cycle. Based on these results
we propose that S. fusiforme is a lead candidate for bioac-
tivity guided isolation and identification of active com-
pounds mediating the observed HIV-1 inhibition.
Identification of these compounds will allow investiga-
tion of the precise mechanisms of inhibition as well as
standardization of the whole extract for potential in vivo
use, and for development of novel antiretroviral drugs
and microbicides.
Methods
Generation of aqueous extract from S. fusiforme plant 
material
Dried S. fusiforme was obtained from the wholesale dis-
tributor, South Project LTD. Hong Kong, China. To con-
firm content and consistency, each separate shipment was
first identified botanically, and then incubated at 55°C
for 6 hours to eliminate any residual moisture. The dried
material was briefly washed in cold water to remove any
debris or loose particulate matter, weighed and resus-
pended to 100 mg/ml H20 in covered sterile glass beakers,
and boiled at 100°C for one hour. Hot water extracts were
allowed to cool to room temperature, then filtered three
times through a Whatman filter paper #2, and autoclaved
for 20 minutes. Each preparation was centrifuged at
100,000 × g for 1 h to remove any additional particulate
matter, aliquoted and stored at -20°C until use.
Cells and culture treatments
T cells
1G5 and CEM T cells were obtained from the NIH AIDS
Reagent Repository and cultured in RPMI 1640 suple-
mented with 10% fetal bovine serum (FBS, HyClone) and
penicillin-streptomycin (pen/strep).
Monocyte-derived human macrophages
Monocytes were recovered from peripheral blood mono-
nuclear cells (PBMCs) by countercurrent centrifugal elu-
triation as previously described [30]. Monocytes were
cultured as adherent monolayers (1 × 106 cells/well in 24-
well plates), differentiated for 7 days in Dulbecco's modi-
fied Eagle's medium (DMEM) supplemented with macro-
phage colony stimulating factor (M-CSF, a generous gift
from Wyeth, Cambridge, MA). Confluent cultures of fully
differentiated macrophages were infected with HIV-1
CCR5-tropic ADA primary isolate, as indicated in Figure
legends.
Isolation and culture of fetal microglial cells
Fetal microglial cells were isolated from second-trimester
(gestational age, 17–19 weeks) human fetal brain tissue
obtained from elective abortions in full compliance with
National Institutes of Health (NIH) guidelines, as previ-
ously described [30]. Briefly, the tissue was washed with
cold Hanks Balanced Salt Solution (HBSS, MediaTech),
then mechanically dissociated and digested with 0.25%
trypsin (Gibco) for 30 minutes at 37°C; trypsin was neu-
tralized with FBS (HyClone). Single cell suspensions were
plated in DMEM supplemented with 10% FBS, 1000 U/
ml M-CSF, and pen/strep. The mixed cultures were main-
tained at 37°C for 7 days and the media was fully
exchanged to remove any cellular debris. The microglial
cells, released upon further incubation, were collected and
purified by preferential adhesion. Microglia were cultured
as adherent monolayers at a density of 0.1 × 106 cells/well
in 24-well plates, and were infected as described in Figure
legends.
Human fetal astrocytes
Fetal astrocytes were isolated from second-trimester (ges-
tational age, 17–19 weeks) human fetal brains obtained
from elective abortions in full compliance with National
Institutes of Health (NIH) guidelines, as previously
described [35]. Briefly, highly homogenous preparations
of astrocytes were obtained using high-density culture
conditions in the absence of growth factors in F12 Dul-
becco's modified Eagle's medium (GIBCO-BRL, Gaithers-
burg, Md.) containing 10% FBS, pen/strep, and
gentamycin. Cultures were regularly monitored for
expression of the astrocytic marker glial fibrillary acidic
protein (GFAP) and either HAM56 or CD68 to identify
cells of monocyte/macrophage lineage. Only cultures that
contained 99% GFAP-positive cells and rare or no detect-
a b l e  HA M 5 6 - o r  CD 6 8 - po s i t i v e  ce l l s  w e re  u s e d i n  o ur
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Cell culture treatments
Before infection, cells were grown for 24 h in culture
media with the indicated concentration of either S. fusi-
forme extract, or with 10-6 M ddC, washed 3 times with
HBSS (GIBCO-BRL), and infected as indicated. After infec-
tion cells were washed 3 times, and returned to culture
with same concentration of each treatment for the dura-
tion of experiment.
HIV-1 molecular clones, envelope expression vectors, and 
generation of pseudotyped HIV-1
T cell tropic HIV-1 molecular clone NL4-3 expresses all
known HIV-1 proteins [38], and it was used to infect T cell
experimental systems. VSV/NL4-3 viral stocks were pre-
pared by cotransfection of intact NL4-3 DNA (pNL4-3)
and VSV envelope expression vector (pL-VSV-G). The VSV-
G expression vector pL-VSV-G was obtained from M.
Emerman; it contains a VSV-G insert in the pcDNA expres-
sion vector modified by replacing the cytomegalovirus
promoter with the HIV-1 long terminal repeat [39]. High-
titer virus stocks, including pseudotyped virus, were pro-
duced in early passage 293T human embryonic kidney
cells transfected with the respective DNA by calcium phos-
phate precipitation [40], as previously described [35].
Cell-free viral stocks were tested for HIV-1 p24 core anti-
gen content by enzyme-linked immunosorbent assay
(ELISA) using HIV-1 Ag kit as specified by the manufac-
turer (Coulter, Hialeah, Fla). Titers of infectious virus were
determined by multinuclear activation of β-galactosidase
indicator (MAGI) assay [41]. In our hands, a multiplicity
of infection of 1 for CD4-positive T cells is equivalent to
approximately 1 pg of viral p24 per cell [35]. Macrophage
and microglial cells infections were performed using the
HIV-1 CCR5-tropic primary isolate ADA, as previously
described [30].
Infections and analysis of HIV-1 expression by luciferase 
gene expression and by p24 ELISA
T cells, confluent cultures of macrophages, microglial
cells, or human fetal astrocytes were infected with native
or pseudotyped HIV-1 at the multiplicity of infection
(moi) as indicated in the Figure legends, and were washed
three times with HBSS (GIBCO-BRL) before being
returned to culture. At the indicated times after infection,
equal number of viable cells normalized by CellTiter 96
Non-Radioactive Cell proliferation Assay [(3-(4,5-Dime-
thyl-2-thiazolyl)-2,5-dephenyltetrazolium (MTT)] kit, or
by trypan blue exclusion assay, were tested for luciferase
expression using Luciferase Assay System kit (Promega) as
specified by the manufacturer. Cell-free supernatants were
tested for HIV-1 p24 core antigen content by ELISA using
the HIV-1 Ag kit as specified by the manufacturer (Coul-
ter, Hialeah, Fla).
Infected T cell cultures were analyzed for syncytium for-
mation at the indicated time points after infection by vis-
ualizing cells under an Olympus BH-2 fluorescence
microscope, and at least 4 separate wells from a 12-well
plate (Costar), from identical experimental systems were
analyzed.
Calculation of percent inhibition of infection
Percent (%) inhibition was determined from either luci-
ferase expression or p24 content, utilizing the following
formula:
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